EZElisa™人巨噬细胞清道夫受体1（MSR1）ELISA
试剂盒-EZElisa™ Human Macrophage Scavenger Receptor 1 (MSR1) ELISA Kit- 询价
- Biogradetech
- 美国
- A-QEK03354-96wells
- 2025年07月15日
企业认证
相关产品推荐更多 >
Horse Heat Shock 70kDa Protein 8 ELISA Kit/Horse Heat Shock 70kDa Protein 8 ELISA Kit
询价
EZElisa™大鼠可溶性分化抗原14（sCD14）ELISA试剂盒-EZElisa™ Rat Soluble Cluster of Differentiation 14 (sCD14) ELISA Kit
询价
EZElisa™人2（3-DPG）ELISA试剂盒-EZElisa™ Human 2 (3-Disphosphoglycerate (2 (3-DPG) ELISA Kit
询价
Camel Procollagen I ELISA Kit/Camel Procollagen I ELISA Kit
询价
Mouse RPE-spondin ELISA Kit/Mouse RPE-spondin ELISA Kit
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
运输过程中保存：2-8℃
- 保质期：
1年
- 英文名：
EZElisa™ Human Macrophage Scavenger Receptor 1 (MSR1) ELISA Kit
- 库存：
100
- 供应商：
艾美捷科技
EZElisa™人巨噬细胞清道夫受体1（MSR1）ELISA试剂盒，EZElisa™ Human Macrophage Scavenger Receptor 1 (MSR1) ELISA Kit，巨噬细胞清道夫受体1（MSR1）ELISA试剂盒, Macrophage Scavenger Receptor 1 (MSR1) ELISA Kit
产品名称：EZElisa™人裂殖子表面蛋白-2（MSP-2）ELISA试剂盒-EZElisa™ Human Macrophage Scavenger Receptor 1 (MSR1) ELISA Kit
产品货号：A-QEK03354-96wells
产品规格：96wells
Enzyme Immunoassay for the estimation of Macrophage Scavenger Receptor 1 (MSR1) in serum and plasma, tissue homogenates and other biological fluids.
种属：Human
检测方法：比色法
检测范围：0.312 - 20 ng/ml
该EZElisa™人巨噬细胞清道夫受体1（MSR1）ELISA试剂盒ELISA的特点包括：即用即用的操作步骤标准化和高重复性批次之间的一致性准确性和精确性经过七个点的验证，符合金环标准质量ELISA的要求，这是Biogradetech质量的基准标志。EZElisa™ ELISA试剂盒用于评估样品中的特定生物标志物，样品可以是血清
运输过程中保存：2-8℃
点击：EZElisa™人裂殖子表面蛋白-2（MSP-2）ELISA试剂盒-EZElisa™ Human Macrophage Scavenger Receptor 1 (MSR1) ELISA Kit更多Biogradetech产品信息价格，货期，产品说明，百度搜“艾美捷科技”进入官网网站，查看具体产品且快速下单。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Identification of Scavenger Receptor Ligands
high-throughput screening of complex mixtures. The assay successfully identified bacterial and plasma ligands for macrophage scavenger receptor A and can be adapted to screen for novel exogenous or endogenous ligands for any immune receptor of interest.
Acute myeloid leukemia (AML) has an annual incidence of 2.4 cases per 100,000 persons and is the most common form of acute leukemia in adults (1 , 2 ). AML is a model for drug-resistant human cancers, and current therapies for AML possess
Adjuvant Activity on Murine and Human Macrophages
and culture of murine macrophages is described, and the use of macrophages derived from gene-deficient mice is proposed to define receptor usage. Novel adjuvants may be tested for their capacity to induce cytokines, chemokines and the expression
技术资料暂无技术资料 索取技术资料
